Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C

Michi M Shinohara; Claudia Davis; John Olerud

Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C

J Drugs Dermatol. 2009 Sep;8(9):870-2.

Authors

Michi M Shinohara¹, Claudia Davis, John Olerud

Affiliation

¹ Division of Dermatology, Department of Medicine, University Washington, Medical Center, Seattle, WA 98195-6524, USA. [email protected]

PMID: 19746680

Abstract

Autoimmune phenomena are common in both hepatitis C infection and interferon alfa treatment; however, the development of antiphospholipid syndrome is rare. This article reports the case of a patient who developed antiphospholipid syndrome in addition to cutaneous sarcoidosis in the setting of pegylated interferon alfa and ribavirin treatment for hepatitis C.

Publication types

Case Reports

MeSH terms

Antiphospholipid Syndrome / chemically induced*
Antiviral Agents / adverse effects*
Antiviral Agents / therapeutic use
Female
Hepatitis C, Chronic / drug therapy
Humans
Interferon-alpha / adverse effects
Interferon-alpha / therapeutic use
Middle Aged
Polyethylene Glycols / chemistry
Ribavirin / adverse effects
Ribavirin / therapeutic use
Sarcoidosis / chemically induced*

Substances

Antiviral Agents
Interferon-alpha
Polyethylene Glycols
Ribavirin